



SDI Review Form 1.6

Journal Name:	International Journal of Biochemistry Research & Review
Manuscript Number:	Ms_IJBCRR_25286
Title of the Manuscript:	Oxidized-LDL, Toll-like receptor 4, Lipocalin2 and Omentin1: Role in diabetic nephropathy
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	In my opinion there are some limitations of this study: 1) The number of studied patients is not very high in each group. 2) As the authors well know, the detection of LDL-ox antibodies are only one method to study oxidative stress, but not the best way to study it, - TBARS, lag phase, etc- . This method only measures lipidic stress, but not other oxidative stress, like nitrosinate or carbonyl stress, important in the pathogenic mechanisms for kidney damage, especially in DM. 3) The patients in the macroalbuminuria group are patients with a bad DM control (HbA1c 8,7%, FBS 283 mg/dL). Therefore the value of LCN2 as an "early" marker is not well substantiated in the study. You need to study proteinuric patients with better metabolic control and to test if, in these kind of DM patient, LCN2 maintain its value as an "early" marker of kidney damage.	We appreciated the constructive criticisms of the reviewer and the valuable comments that have helped us greatly to improve our manuscript. I have addressed each of their concerns as outlined below. 1) As ethical approval and patient consent were obligatory many patient refuse to be involved in research in addition our research is not funded at all. 2) I agree to your comment but we already on our on-going research we try to study other oxidative stress parameters and its relation to diabetic kidney damage. But in this research our aim was to know the role played by those studied biomarker and we take ox-LDL as a linker and our research is not funded at all 3) This is an excellent idea to be involved in our on-going research. however in this current research most of our patients were collected from inpatient and outpatient clinic and most of these patients were come for blood sugar regulation and this is was one of the limitations but it will be taken in consideration in our on-going research in DM
<u>Minor</u> REVISION comments	The values expressed in "mg/dl" may be changed to "mg/dL".	
<u>Optional/General</u> comments	No other comments	